332 related articles for article (PubMed ID: 22584552)
1. The effects of MDCO-2010, a serine protease inhibitor, on activated clotting time in blood obtained from volunteers and cardiac surgical patients.
Kim H; Szlam F; Tanaka KA; van de Locht A; Ogawa S; Levy JH
Anesth Analg; 2012 Aug; 115(2):244-52. PubMed ID: 22584552
[TBL] [Abstract][Full Text] [Related]
2. Monitoring activated clotting time for combined heparin and aprotinin application: in vivo evaluation of a new aprotinin-insensitive test using Sonoclot.
Ganter MT; Monn A; Tavakoli R; Genoni M; Klaghofer R; Furrer L; Honegger H; Hofer CK
Eur J Cardiothorac Surg; 2006 Aug; 30(2):278-84. PubMed ID: 16828293
[TBL] [Abstract][Full Text] [Related]
3. Correlations between activated clotting time values and heparin concentration measurements in young infants undergoing cardiopulmonary bypass.
Guzzetta NA; Monitz HG; Fernandez JD; Fazlollah TM; Knezevic A; Miller BE
Anesth Analg; 2010 Jul; 111(1):173-9. PubMed ID: 20519414
[TBL] [Abstract][Full Text] [Related]
4. Celite and kaolin produce differing activated clotting times during cardiopulmonary bypass under aprotinin therapy.
Feindt P; Seyfert UT; Volkmer I; Straub U; Gams E
Thorac Cardiovasc Surg; 1994 Aug; 42(4):218-21. PubMed ID: 7529949
[TBL] [Abstract][Full Text] [Related]
5. In vitro effects of aprotinin on activated clotting time measured with different activators.
Wang JS; Lin CY; Hung WT; Thisted RA; Karp RB
J Thorac Cardiovasc Surg; 1992 Oct; 104(4):1135-40. PubMed ID: 1383640
[TBL] [Abstract][Full Text] [Related]
6. Aprotinin does not prolong the Sonoclot aprotinin-insensitive activated clotting time.
Dong Y; Nuttall GA; Oliver WC; Agarwal S; Ereth MH
J Clin Anesth; 2007 Sep; 19(6):424-8. PubMed ID: 17967670
[TBL] [Abstract][Full Text] [Related]
7. Effects of low doses of aprotinin on clotting times activated with celite and kaolin.
Farooqi N; De Hert S; Vlaeminck R; De Bakker A; Govaerts E; Vermeyen K
Acta Anaesthesiol Belg; 1993; 44(3):87-92. PubMed ID: 7508668
[TBL] [Abstract][Full Text] [Related]
8. In vivo and in vitro evaluation of the heparin management test versus the activated coagulation time for monitoring anticoagulation level in aprotinin-treated patients during cardiac surgery.
Kim YS; Murkin JM; Adams SJ
Heart Surg Forum; 2004; 7(6):E599-604. PubMed ID: 15769695
[TBL] [Abstract][Full Text] [Related]
9. The prolonged activated clotting time (ACT) with aprotinin depends on the type of activator used for measurement.
Wendel HP; Heller W; Gallimore MJ; Bantel H; Müller-Beissenhirtz H; Hoffmeister HE
Blood Coagul Fibrinolysis; 1993 Feb; 4(1):41-5. PubMed ID: 7681331
[TBL] [Abstract][Full Text] [Related]
10. Effects of heparin, haemodilution and aprotinin on kaolin-based activated clotting time: in vitro comparison of two different point of care devices.
Dalbert S; Ganter MT; Furrer L; Klaghofer R; Zollinger A; Hofer CK
Acta Anaesthesiol Scand; 2006 Apr; 50(4):461-8. PubMed ID: 16548858
[TBL] [Abstract][Full Text] [Related]
11. Measurement of activated coagulation time in children: evaluation of the blood-saving kaolin i-STAT activated coagulation time technique in pediatric cardiac anesthesia.
Ulmer FF; Baulig W; Béttex D; Spielmann N; Bürki C; Weiss M
J Cardiothorac Vasc Anesth; 2011 Jun; 25(3):395-401. PubMed ID: 21376632
[TBL] [Abstract][Full Text] [Related]
12. Aprotinin prolongs activated and nonactivated whole blood clotting time and potentiates the effect of heparin in vitro.
Despotis GJ; Filos KS; Levine V; Alsoufiev A; Spitznagel E
Anesth Analg; 1996 Jun; 82(6):1126-31. PubMed ID: 8638779
[TBL] [Abstract][Full Text] [Related]
13. Response of kaolin ACT to heparin: evaluation with an automated assay and higher heparin doses.
Despotis GJ; Alsoufiev AL; Spitznagel E; Goodnough LT; Lappas DG
Ann Thorac Surg; 1996 Mar; 61(3):795-9. PubMed ID: 8619695
[TBL] [Abstract][Full Text] [Related]
14. Influence of high-dose aprotinin on anticoagulation, heparin requirement, and celite- and kaolin-activated clotting time in heparin-pretreated patients undergoing open-heart surgery. A double-blind, placebo-controlled study.
Dietrich W; Dilthey G; Spannagl M; Jochum M; Braun SL; Richter JA
Anesthesiology; 1995 Oct; 83(4):679-89; discussion 29A-30A. PubMed ID: 7574046
[TBL] [Abstract][Full Text] [Related]
15. Anticoagulation and anticoagulation reversal with cardiac surgery involving cardiopulmonary bypass: an update.
Despotis GJ; Joist JH
J Cardiothorac Vasc Anesth; 1999 Aug; 13(4 Suppl 1):18-29; discussion 36-7. PubMed ID: 10468245
[TBL] [Abstract][Full Text] [Related]
16. Antithrombin III during cardiac surgery: effect on response of activated clotting time to heparin and relationship to markers of hemostatic activation.
Despotis GJ; Levine V; Joist JH; Joiner-Maier D; Spitznagel E
Anesth Analg; 1997 Sep; 85(3):498-506. PubMed ID: 9296400
[TBL] [Abstract][Full Text] [Related]
17. Kaolin-based activated coagulation time measured by sonoclot in patients undergoing cardiopulmonary bypass.
Ganter MT; Monn A; Tavakoli R; Klaghofer R; Zollinger A; Hofer CK
J Cardiothorac Vasc Anesth; 2007 Aug; 21(4):524-8. PubMed ID: 17678778
[TBL] [Abstract][Full Text] [Related]
18. Monitoring of heparin-induced anticoagulation with kaolin-activated clotting time in cardiac surgical patients treated with aprotinin.
Wang JS; Lin CY; Hung WT; Karp RB
Anesthesiology; 1992 Dec; 77(6):1080-4. PubMed ID: 1281624
[TBL] [Abstract][Full Text] [Related]
19. Effect of aprotinin on activated clotting time, whole blood and plasma heparin measurements.
Despotis GJ; Joist JH; Joiner-Maier D; Alsoufiev AL; Triantafillou AN; Goodnough LT; Santoro SA; Lappas DG
Ann Thorac Surg; 1995 Jan; 59(1):106-11. PubMed ID: 7529483
[TBL] [Abstract][Full Text] [Related]
20. More effective suppression of hemostatic system activation in patients undergoing cardiac surgery by heparin dosing based on heparin blood concentrations rather than ACT.
Despotis GJ; Joist JH; Hogue CW; Alsoufiev A; Joiner-Maier D; Santoro SA; Spitznagel E; Weitz JI; Goodnough LT
Thromb Haemost; 1996 Dec; 76(6):902-8. PubMed ID: 8972009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
